The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*

Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first t...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G, Laubach, Jacob P, Schlossman, Robert L, Ghobrial, Irene M, Mitsiades, Constantine S, Rosenblatt, Jacalyn, Mahindra, Anuj, Raje, Noopur, Munshi, Nikhil, Anderson, Kenneth C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267050/
https://www.ncbi.nlm.nih.gov/pubmed/21991938
http://dx.doi.org/10.1111/j.1600-0609.2011.01721.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267050/
https://www.ncbi.nlm.nih.gov/pubmed/21991938
http://dx.doi.org/10.1111/j.1600-0609.2011.01721.x

Ejemplares similares